Drug Watch

Latest News

New Research Highlights Zabalafin Hydrogel's Novel Multi-Targeted Approach to AD Treatment
New Research Highlights Zabalafin Hydrogel's Novel Multi-Targeted Approach to AD Treatment

July 2nd 2025

A new paper highlights Alphyn Biologics' Zabalafin Hydrogel as a promising multi-target therapy for atopic dermatitis, addressing inflammation, itch, and bacterial complications.

FDA Grants Rare Pediatric Disease Designation to QRX003 for Netherton Syndrome
FDA Grants Rare Pediatric Disease Designation to QRX003 for Netherton Syndrome

June 27th 2025

REZOLVE-AD Trial Results Show Promise for Rezpegaldesleukin in Atopic Dermatitis
REZOLVE-AD Trial Results Show Promise for Rezpegaldesleukin in Atopic Dermatitis

June 27th 2025

Galderma Announces Clinical Trials Evaluating Nemolizumab for SSc and CPUO
Galderma Announces Clinical Trials Evaluating Nemolizumab for SSc and CPUO

June 26th 2025

More News

© 2025 MJH Life Sciences

All rights reserved.